By G HossainPosted on February 4, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like MPS II moving into the spotlight. From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era Post navigation 2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs